ABIVAX Société Anonyme (AAVXF)
USD 11.05
(0.0%)
USD 11.05
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -147.74 Million EUR | -111.52% |
| 2022 | -69.84 Million EUR | -68.89% |
| 2021 | -41.35 Million EUR | -10.14% |
| 2020 | -37.55 Million EUR | -22.58% |
| 2019 | -30.63 Million EUR | -93.6% |
| 2018 | -15.82 Million EUR | -40.99% |
| 2017 | -11.22 Million EUR | 21.56% |
| 2016 | -14.3 Million EUR | 10.32% |
| 2015 | -15.95 Million EUR | -96.98% |
| 2014 | -8.09 Million EUR | -37.43% |
| 2013 | -5.89 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -40.81 Million EUR | 0.0% |
| 2024 Q1 | -40.81 Million EUR | 14.77% |
| 2023 Q3 | -47.89 Million EUR | 7.81% |
| 2023 FY | -147.74 Million EUR | -111.52% |
| 2023 Q1 | -25.97 Million EUR | 35.53% |
| 2023 Q2 | -51.95 Million EUR | -100.0% |
| 2023 Q4 | -47.89 Million EUR | 0.0% |
| 2022 Q3 | -19.77 Million EUR | 33.07% |
| 2022 FY | -69.84 Million EUR | -68.89% |
| 2022 Q4 | -40.29 Million EUR | -103.72% |
| 2022 Q2 | -29.55 Million EUR | -179.03% |
| 2022 Q1 | -10.59 Million EUR | 57.34% |
| 2021 Q4 | -24.82 Million EUR | -91.55% |
| 2021 Q1 | -8.26 Million EUR | 62.65% |
| 2021 Q2 | -16.53 Million EUR | -100.0% |
| 2021 FY | -41.35 Million EUR | -10.14% |
| 2021 Q3 | -12.96 Million EUR | 21.6% |
| 2020 Q4 | -22.12 Million EUR | -100.0% |
| 2020 Q2 | -15.42 Million EUR | -100.0% |
| 2020 Q3 | -11.06 Million EUR | 28.26% |
| 2020 Q1 | -7.71 Million EUR | 53.16% |
| 2020 FY | -37.55 Million EUR | -22.58% |
| 2019 Q3 | -8.23 Million EUR | 41.92% |
| 2019 Q4 | -16.46 Million EUR | -100.0% |
| 2019 FY | -30.63 Million EUR | -93.6% |
| 2019 Q1 | -7.08 Million EUR | -65.21% |
| 2019 Q2 | -14.17 Million EUR | -100.0% |
| 2018 FY | -15.82 Million EUR | -40.99% |
| 2018 Q3 | -4.28 Million EUR | -18.4% |
| 2018 Q2 | -3.62 Million EUR | 0.0% |
| 2018 Q1 | -3.62 Million EUR | -27.71% |
| 2018 Q4 | -4.28 Million EUR | 0.0% |
| 2017 Q1 | -2.77 Million EUR | 8.04% |
| 2017 Q2 | -2.77 Million EUR | 0.0% |
| 2017 Q3 | -2.83 Million EUR | -2.23% |
| 2017 Q4 | -2.83 Million EUR | 0.0% |
| 2017 FY | -11.22 Million EUR | 21.56% |
| 2016 Q2 | -4.13 Million EUR | 0.0% |
| 2016 FY | -14.3 Million EUR | 10.32% |
| 2016 Q3 | -3.01 Million EUR | 27.07% |
| 2016 Q1 | -4.13 Million EUR | 5.82% |
| 2016 Q4 | -3.01 Million EUR | 0.0% |
| 2015 Q1 | -3.58 Million EUR | -61.96% |
| 2015 Q2 | -3.58 Million EUR | 0.0% |
| 2015 Q3 | -4.39 Million EUR | -22.52% |
| 2015 Q4 | -4.39 Million EUR | 0.0% |
| 2015 FY | -15.95 Million EUR | -96.98% |
| 2014 FY | -8.09 Million EUR | -37.43% |
| 2014 Q4 | -2.21 Million EUR | 0.0% |
| 2014 Q2 | -326.5 Thousand EUR | 0.0% |
| 2014 Q1 | -326.5 Thousand EUR | 0.0% |
| 2014 Q3 | -2.21 Million EUR | -577.95% |
| 2013 FY | -5.89 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -97.084% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -2146.617% |
| SQZ Biotechnologies Company | -79.46 Million USD | -85.921% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 378.865% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 326.828% |
| Mesoblast Limited | -87.95 Million USD | -67.97% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -8015.228% |
| Genus plc | 7.9 Million USD | 1970.127% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -1256.441% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -3881.959% |
| Marizyme, Inc. | -65.34 Million USD | -126.086% |
| ContraFect Corporation | -65.15 Million USD | -126.759% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -1570.511% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -2923.702% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -8452.466% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -5007.879% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -1733.075% |
| MultiCell Technologies, Inc. | -380.07 USD | -38871686.776% |
| Accustem Sciences Inc. | -3.74 Million USD | -3843.499% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -185.808% |
| EV Biologics, Inc. | -1.26 Million USD | -11559.383% |
| Q BioMed Inc. | -2.05 Million USD | -7099.479% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -3857.675% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -23261.538% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -6105.295% |
| Biomind Labs Inc. | -1.21 Million USD | -12066.49% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -1300.645% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -1769.395% |
| Skye Bioscience, Inc. | -37.64 Million USD | -292.458% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -6708.879% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -986411.752% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -2015.759% |
| IMV Inc. | -36.48 Million USD | -304.926% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -830.854% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -2439.687% |
| GB Sciences, Inc. | -1.36 Million USD | -10749.856% |
| Alpha Cognition Inc. | -13.77 Million USD | -972.712% |
| HST Global, Inc. | -146.21 Thousand USD | -100946.44% |
| CSL Limited | 2.64 Billion USD | 105.592% |
| Halberd Corporation | -79.67 Thousand USD | -185325.975% |
| Enzolytics Inc. | -2.17 Million USD | -6686.927% |
| Resverlogix Corp. | -3.61 Million USD | -3992.521% |
| Affymax, Inc. | -14.42 Million USD | -924.265% |
| SYBLEU INC | -180.3 Thousand USD | -81839.391% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -4558.458% |
| argenx SE | -295.05 Million USD | 49.928% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -136.01% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 150855.102% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -3618.607% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -4782.135% |
| AVAX Technologies, Inc. | -6.41 Million USD | -2203.525% |
| Zenith Capital Corp. | -10.59 Million USD | -1294.3% |
| Genscript Biotech Corporation | -95.47 Million USD | -54.739% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -635559.582% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -3463.49% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -244338.301% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -147.365% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -4663.09% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -13889.775% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -7479.329% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -3768.552% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -7268.156% |
| BioStem Technologies, Inc. | -8.48 Million USD | -1641.604% |
| ONE Bio Corp. | 8.67 Million USD | 1802.738% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -33373.126% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -10963.095% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -8319.332% |
| Agentix Corp. | -1.37 Million USD | -10650.896% |
| LadRx Corporation | 400.44 Thousand USD | 36994.14% |
| Cell Source, Inc. | -5.32 Million USD | -2676.435% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -35458.957% |
| Regen BioPharma, Inc. | 1.02 Million USD | 14534.67% |
| Regen BioPharma, Inc. | 1.02 Million USD | 14534.67% |
| NovAccess Global Inc. | -4.76 Million USD | -2997.803% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 2233.555% |
| Itoco Inc. | -1.86 Million USD | -7804.783% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -3225.579% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -8752.007% |
| Kadimastem Ltd | -3.3 Million USD | -4366.956% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -53937.644% |
| CytoDyn Inc. | -49.84 Million USD | -196.423% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -186834.572% |
| Mobile Lads Corp. | -2.26 Million USD | -6427.66% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -64662.172% |
| Qrons Inc. | -789.34 Thousand USD | -18616.737% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -15591.498% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -6976.748% |
| Rebus Holdings, Inc. | -1.02 Million USD | -14384.314% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -9060.824% |
| International Stem Cell Corporation | -131 Thousand USD | -112678.626% |
| Bioxytran, Inc. | -4.28 Million USD | -3351.868% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -272121.403% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -5738.956% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -207.331% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -6888.647% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -18819.511% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -4563.51% |
| Neutra Corp. | -233.46 Thousand USD | -63181.434% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -628.106% |
| PureTech Health plc | -65.69 Million USD | -124.881% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -594.706% |
| IXICO plc | -1.17 Million USD | -12441.596% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -1388.264% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -158.612% |
| CSL Limited | 2.64 Billion USD | 105.592% |
| Cellectis S.A. | -103.17 Million USD | -43.195% |